CRP and age-related macular degeneration: Georgakopoulos et al. confirmed that a single dose of aflibercept did not affect biomarkers associated with CV risks (homocysteine, total cholesterol, triglycerides, HDL‐c, LDL‐c and CRP) in AMD patients.16